CY1124783T1 - Συνθεσεις για in situ ενεσιμα βιοαποδομησιμα εμφυτευματα - Google Patents

Συνθεσεις για in situ ενεσιμα βιοαποδομησιμα εμφυτευματα

Info

Publication number
CY1124783T1
CY1124783T1 CY20211101041T CY211101041T CY1124783T1 CY 1124783 T1 CY1124783 T1 CY 1124783T1 CY 20211101041 T CY20211101041 T CY 20211101041T CY 211101041 T CY211101041 T CY 211101041T CY 1124783 T1 CY1124783 T1 CY 1124783T1
Authority
CY
Cyprus
Prior art keywords
biodegradable implants
compositions
substance
injectable biodegradable
lactic acid
Prior art date
Application number
CY20211101041T
Other languages
English (en)
Inventor
Ibon Guierro Aduriz
María Teresa GÓMEZ OCHOA
Original Assignee
Laboratorios Farmaceuticos Rovi, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Farmaceuticos Rovi, S.A. filed Critical Laboratorios Farmaceuticos Rovi, S.A.
Publication of CY1124783T1 publication Critical patent/CY1124783T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Τα ενέσιμα σκευάσματα μακράς διάρκειας δράσης, αποτελούμενα από βιοσυμβατό πολυμερές, το οποίο είναι ένα πολυμερές ή ένα συμπολυμερές με βάση το γαλακτικό οξύ ή/και το γαλακτικό οξύ μαζί με γλυκολικό οξύ με αναλογία σε ένα εύρος από 48:52 έως 100:0, έναν διαλύτη αναμίξιμο με νερό με διπολική ροπή περίπου 3,7-4,5 D και διηλεκτρική σταθερά ανάμεσα στο 30 και 50 και μια ουσία, κρίθηκαν κατάλληλα για τον in situ σχηματισμό βιοαποδομήσιμων εμφυτευμάτων που μπορούν να προκαλέσουν θεραπευτικά επίπεδα της ουσίας στο πλάσμα από την πρώτη ημέρα και για τουλάχιστον 14 ημέρες.
CY20211101041T 2010-05-31 2021-11-29 Συνθεσεις για in situ ενεσιμα βιοαποδομησιμα εμφυτευματα CY1124783T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10382153.4A EP2394663B1 (en) 2010-05-31 2010-05-31 Compositions for injectable in-situ biodegradable implants

Publications (1)

Publication Number Publication Date
CY1124783T1 true CY1124783T1 (el) 2022-11-25

Family

ID=43301929

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211101041T CY1124783T1 (el) 2010-05-31 2021-11-29 Συνθεσεις για in situ ενεσιμα βιοαποδομησιμα εμφυτευματα

Country Status (21)

Country Link
US (2) US10058504B2 (el)
EP (2) EP2394663B1 (el)
JP (1) JP5923493B2 (el)
CN (1) CN102933234A (el)
BR (1) BR112012030707A2 (el)
CA (1) CA2800641C (el)
CY (1) CY1124783T1 (el)
DK (1) DK2582395T3 (el)
EA (1) EA024211B1 (el)
ES (2) ES2897976T3 (el)
FI (1) FI2582395T3 (el)
HR (2) HRP20211853T1 (el)
HU (3) HUE057236T2 (el)
LT (2) LT2394663T (el)
MX (1) MX346167B (el)
PL (2) PL2394663T3 (el)
PT (2) PT2394663T (el)
RS (2) RS64451B1 (el)
SI (2) SI2394663T1 (el)
WO (1) WO2011151356A2 (el)
ZA (1) ZA201209394B (el)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
ES2390439B1 (es) * 2012-08-03 2013-09-27 Laboratorios Farmacéuticos Rovi, S.A. Composición inyectable
LT2394663T (lt) 2010-05-31 2022-02-10 Laboratorios Farmaceuticos Rovi, S.A. Kompozicijos, skirtos įšvirkščiamiems in situ biologiškai skaidiems implantams
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
HUE029895T2 (en) 2010-05-31 2017-04-28 Farm Rovi Lab Sa Antipsychotic injectable depot preparation
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
PL2529757T3 (pl) * 2011-05-31 2014-04-30 Farm Rovi Lab Sa Formulacja implantu zawierającego paliperydon
SI2529756T1 (sl) * 2011-05-31 2021-09-30 Laboratorios Farmaceuticos Rovi, S.A. Formulacija vsadka z risperidonom in/ali paliperidonom
US8935726B2 (en) 2012-05-11 2015-01-13 Comcast Cable Communications, Llc Generation of dynamic content interfaces
BR112015022023B1 (pt) 2013-03-11 2022-12-06 Durect Corporation Composição de liberação controlada injetável compreendendo transportador líquido de alta viscosidade
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CN116942677A (zh) 2015-09-21 2023-10-27 梯瓦制药国际有限责任公司 缓释奥氮平制剂
CN107811967B (zh) * 2016-09-09 2021-08-24 中国疾病预防控制中心寄生虫病预防控制所(国家热带病研究中心) 抗寄生虫药物原位固化缓释注射剂及其制备方法
KR20190066608A (ko) * 2016-09-23 2019-06-13 델포어, 인코포레이티드 소분자 치료제 화합물 조성물
WO2018070940A1 (en) * 2016-10-14 2018-04-19 Nanyang Technological University An injectable composition for localized controlled and sustained delivery system
EP3600258A1 (en) 2017-03-20 2020-02-05 Teva Pharmaceuticals International GmbH Sustained release olanzapine formulaitons
WO2019097242A1 (en) * 2017-11-16 2019-05-23 Persica Pharmaceuticals Ltd. Linezolid formulations
PE20210047A1 (es) * 2018-06-12 2021-01-08 Farm Rovi Lab Sa Composicion inyectable
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
AU2022308198A1 (en) 2021-07-06 2024-02-01 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome
TW202313047A (zh) 2021-09-21 2023-04-01 西班牙商禾霏藥品實驗室有限公司 抗精神病可注射儲積型組合物

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
BE758156R (fr) 1970-05-13 1971-04-28 Ethicon Inc Element de suture absorbable et sa
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4523591A (en) 1982-10-22 1985-06-18 Kaplan Donald S Polymers for injection molding of absorbable surgical devices
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5620700A (en) 1990-10-30 1997-04-15 Alza Corporation Injectable drug delivery system and method
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
ATE288270T1 (de) 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv Mikroverkapselte 1,2-benzazole
US5620770A (en) 1995-06-01 1997-04-15 Superior Environmental Products, Inc. Fifth wheel insert, laminate composite and method of construction
ATE203157T1 (de) 1996-12-20 2001-08-15 Alza Corp Injizierbare depotgelzubereitung und herstellungsverfahren
KR100289471B1 (ko) * 1998-01-19 2001-09-17 김충섭 휀타닐계마취제의이식형서방성제제
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
EP1248596B1 (de) * 2000-01-11 2007-03-07 Roland Bodmeier Kit zur implantation enthaltend eine trägerphase und ein lösungsmittel
US6604561B2 (en) * 2000-02-11 2003-08-12 Medical Instill Technologies, Inc. Medicament vial having a heat-sealable cap, and apparatus and method for filling the vial
WO2002038185A2 (en) 2000-11-13 2002-05-16 Atrix Laboratories, Inc. Injectable sustained release delivery system with loperamide
US6565080B1 (en) 2001-12-17 2003-05-20 Hewlett-Packard Development Company, L.P. Imaging media loading guide
WO2004064752A2 (en) * 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
WO2004081196A2 (en) 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell- schedule dependent anticancer agents
US20050003007A1 (en) 2003-07-02 2005-01-06 Michele Boix Method of sterilization of polymeric microparticles
DK1660039T3 (en) 2003-07-18 2017-01-16 Oakwood Laboratories L L C PREVENTION OF REDUCTION OF THE POLYMER MOLECULE WEIGHT, THE PREPARATION OF PURPOSES AND GELING IN POLYMER COMPOSITIONS
US8444600B2 (en) * 2003-09-17 2013-05-21 Jae Sang Park Replaceable heating cartridge for use with a warming device for medical treatment
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
AU2005294382A1 (en) 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
DK1824460T3 (en) * 2004-11-10 2015-01-19 Tolmar Therapeutics Inc Stabilized polymeric delivery system
DE102005031868A1 (de) * 2005-07-04 2007-01-18 Biotronik Vi Patent Ag Arzneimitteldepot zur parenteralen, insbesondere intravaskulären Arzneimittelfreisetzung
US8852638B2 (en) * 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
SE0600876L (sv) * 2006-04-20 2007-10-21 Sandvik Intellectual Property Verktyg och skär för spånavskiljande bearbetning med primära och sekundära ingreppsmedel med rotationssymmetrisk form
US8076448B2 (en) 2006-10-11 2011-12-13 Tolmar Therapeutics, Inc. Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction
PL2079767T3 (pl) * 2006-10-11 2015-05-29 Tolmar Therapeutics Inc Wytwarzanie biodegradowalnych poliestrów z właściwościami niskiego wyrzutu przez ekstrakcję płynem nadkrytycznym
FR2908775B1 (fr) * 2006-11-17 2012-08-31 Biomatlante Hydrogel et ses applications biomedicales
PL2115029T3 (pl) 2007-02-15 2016-01-29 Tolmar Therapeutics Inc Poli(laktyd/glikolid) o niskim efekcie nagłego uwalniania i sposoby wytwarzania polimerów
JP5009361B2 (ja) * 2007-03-29 2012-08-22 京セラ株式会社 携帯無線機
JP5599705B2 (ja) * 2007-05-18 2014-10-01 デュレクト コーポレーション 改良されたデポー製剤
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
CL2008003305A1 (es) * 2007-11-06 2009-06-05 M/S Panacea Biotec Ltd Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer.
US8629172B2 (en) * 2008-04-18 2014-01-14 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
ES2390439B1 (es) 2012-08-03 2013-09-27 Laboratorios Farmacéuticos Rovi, S.A. Composición inyectable
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
HUE029895T2 (en) 2010-05-31 2017-04-28 Farm Rovi Lab Sa Antipsychotic injectable depot preparation
LT2394663T (lt) 2010-05-31 2022-02-10 Laboratorios Farmaceuticos Rovi, S.A. Kompozicijos, skirtos įšvirkščiamiems in situ biologiškai skaidiems implantams
SI2529756T1 (sl) 2011-05-31 2021-09-30 Laboratorios Farmaceuticos Rovi, S.A. Formulacija vsadka z risperidonom in/ali paliperidonom
PL2529757T3 (pl) 2011-05-31 2014-04-30 Farm Rovi Lab Sa Formulacja implantu zawierającego paliperydon

Also Published As

Publication number Publication date
MX346167B (es) 2017-03-08
BR112012030707A2 (pt) 2016-11-01
ES2950857T3 (es) 2023-10-16
HUE057236T2 (hu) 2022-04-28
HRP20211853T1 (hr) 2022-03-04
EP2394663B1 (en) 2021-10-13
FI2582395T3 (fi) 2023-08-08
PL2582395T3 (pl) 2023-08-21
CA2800641C (en) 2018-05-22
US10058504B2 (en) 2018-08-28
US20180318208A1 (en) 2018-11-08
ZA201209394B (en) 2013-08-28
HUE063623T2 (hu) 2024-01-28
CA2800641A1 (en) 2011-12-08
MX2012013867A (es) 2013-01-24
PT2582395T (pt) 2023-08-18
WO2011151356A3 (en) 2012-03-22
EA201201570A1 (ru) 2013-09-30
EP2394663A1 (en) 2011-12-14
SI2394663T1 (sl) 2022-02-28
CN102933234A (zh) 2013-02-13
US10195138B2 (en) 2019-02-05
RS53205B (en) 2014-06-30
HRP20230890T1 (hr) 2023-11-10
LT2582395T (lt) 2023-08-10
US20130177603A1 (en) 2013-07-11
HUE054922T2 (hu) 2021-10-28
RS64451B1 (sr) 2023-09-29
DK2582395T3 (da) 2023-08-07
SI2582395T1 (sl) 2023-10-30
ES2897976T3 (es) 2022-03-03
PL2394663T3 (pl) 2022-02-21
LT2394663T (lt) 2022-02-10
EA024211B1 (ru) 2016-08-31
JP2013527213A (ja) 2013-06-27
JP5923493B2 (ja) 2016-05-24
EP2582395B1 (en) 2023-05-10
WO2011151356A2 (en) 2011-12-08
PT2394663T (pt) 2021-11-26
EP2582395A2 (en) 2013-04-24

Similar Documents

Publication Publication Date Title
CY1124783T1 (el) Συνθεσεις για in situ ενεσιμα βιοαποδομησιμα εμφυτευματα
CY1124206T1 (el) Αναστολεις πυριδοπυριμδινονης cdk2/4/6
CY1119531T1 (el) Ενωσεις και συνθεσεις για την ρυθμιση της δραστηριοτητας toy egfr
CY1122475T1 (el) Μια μορφοποιηση φαρμακου καθυστερημενης εκλυσης
CY1124369T1 (el) Συνθεση εμφυτευματος ρισπεριδονης ή/και παλιπεριδονης
CY1121700T1 (el) Σχηματισμοι οξινου αλατος ενος συζυγους πολυμερους-φαρμακου
CY1114975T1 (el) Σκευασμα εμφυτευματος παλιπεριδονης
CY1117207T1 (el) Ιξωδοελαστικες γελες ως νεα υλικα πληρωσης
CY1123626T1 (el) Ετεροκυκλικοι αναστολεις πρωτεϊνικης κινασης
CY1118771T1 (el) Μακροκυκλικα παραγωγα για την αγωγη υπερπλαστικων παθησεων
CY1120460T1 (el) Παραγωγο πυραζολοπυριμιδινης με υποκατεστημενη τη θεση 4, και χρηση αυτου στην παρασκευη φαρμακων
CY1122252T1 (el) Ενεσιμο παρασκευασμα
CY1119843T1 (el) Φαινυλοξικη l-ορνιθινη και μεθοδοι παρασκευης αυτης
CY1116150T1 (el) Παραγωγα οξαδιαζολης και η χρηση τους ως ενισχυτων μεταβοτροπικου υποδοχεα γλουταμικου - 842
CO6640285A2 (es) 5-alquinil-pirimidinas
UA111162C2 (uk) Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
CY1125114T1 (el) Συνθεσεις και μεθοδοι για τη μειωση μειζωνων ανεπιθυμητων καρδιαγγειακων συμβαντων
CY1125157T1 (el) Ενεσιμες συνθεσεις που εμπεριεχουν λετροζολη ή αναστροζολη
EA201691194A1 (ru) Стимуляторы ргц
IN2014CN00827A (el)
CY1109644T1 (el) 2,4-διαμινο-πυριμιδινες ως αναστολεις audora
CY1123056T1 (el) Νεα μορφη χορηγησης της ρασεκαδοτριλης
WO2012009661A3 (en) Conductive biopolymer implant for enhancing tissue repair and regeneration using electromagnetic fields
ITPD20050146A1 (it) Fillers riassorbibili costituiti da liposomi e acido ialuronico e o suoi derivati
CY1123582T1 (el) Προφαρμακα των αναστολεων αντιστροφης μεταγραφασης hiv